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Between 2000 and 2012, the national rate of Neonatal Abstinence Syndrome (NAS) has
increased over 400 percent, from 1.2 to 5.8 per 1,000 live births.1 A region hard-hit by the opioid
epidemic, some Appalachian counties in East Tennessee report NAS rates more than 10 times the
national average, “with rates exceeding 60 per 1,000 live births.”2 Knox County’s NAS incidence
peaked in 2014, at 22.6 per 1,000 live births and has since held steady at just over 20 per 1,000
live births.*3 As concern over the opioid epidemic increases, so have community efforts to
combat it. As evidenced by the opioid epidemic, drug use pervades race, socioeconomic status,
geography, and age; even neonates are not immune to drug addiction.
Dr. Loretta Finnegan first described Neonatal Abstinence Syndrome in the 1970’s. She
developed the first scoring system for babies who exhibited symptoms of withdrawal after birth
to provide a more objective evaluation of the infant’s withdrawal status. Providers still use the
Finnegan scoring system today before, during, and after treatment to monitor progress and adjust
pharmacologic treatment according to its uniform criteria. The Finnegan system assigns scores to
specific symptoms in an itemized list that include central nervous system disturbances such as
high pitched cry and tremors, metabolic and respiratory disturbances including hyperthermia,
and gastrointestinal disturbances like poor feeding and regurgitation. NAS symptoms and criteria
are listed in Table 1.4,5 Providers initially attempt to treat these symptoms with nonpharmacological such as breast-feeding, low-stimulus environments, and swaddling. If these
interventions do not sufficiently manage symptoms, then providers

*

Most recent annual report available is for 2017
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Table 1. Neonatal Abstinence
Syndrome Symptomology.4,5
Central Nervous System
Disturbances

Metabolic, Vasomotor, and
Respiratory Disturbances

Gastrointestinal Disturbances

High pitched crying

Sweating

Excessive sucking

Sleep disturbances

Frequent yawning

Poor feeding

Myoclonic jerks

Mottling

Regurgitation

Hyperactive Moro reflex

Nasal stuﬃness

Projectile vomiting

Tremors

Sneezing

Loose or watery stools

Increased muscle tone

Nasal flaring

Weight Loss

Excoriation

Increased respiratory rate ( > 60/
min), with or without retractions

Convulsions/seizures

Hyperthermia

use pharmacological treatments such as diluted morphine tinctures and phenobarbital. Research
has shown prolonged exposure to opiates poses adverse neural, cognitive, and behavioral
outcomes in the developing brain. Investigating how we can minimize pharmacotherapy
treatment when possible, and promote favorable developmental outcomes is of great importance
as hospitals see increased numbers of NAS patients.
While the health outcomes of babies in the Neonatal Intensive Care Unit (NICU) prove
more than important finances, the financial strain on both families and healthcare systems due to
increased length of stay should not be ignored. Since building a new NICU wing in 2012
specifically for neonates born with NAS, East Tennessee Children’s Hospital (ETCH) spent over
seventy five million dollars to expand it to sixty six private rooms. Babies born with NAS
“experience withdrawal just like adults,” ETCH writes on their site, describing the new NICU
wing. “They have a screech-like cry, claw their faces, and squirm.” This wing is built to limit
stimulation; it has dark lighting, quiet rooms, and special volunteers to comfort the babies.6 In a
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similar attempt to create a less stimulating environment, the University of Tennessee Medical
Center (UTMC) has a NICU wing for NAS babies with a noise level of about 25-30 decibels,
much lower than the noise levels in the open bay, which range from 80-100 decibels. Less than
two miles from ETCH, UTMC has also expanded its NICU in recent years to accommodate
increasing numbers of NAS patients. Just this year, at the end of March, UTMC opened “The
Firefly Cove” to accommodate NAS babies; the previously described, $60 million, new 30-bed
NICU wing. Last year, UTMC admitted 860 babies, and for the past ten years or so, babies with
NAS account for roughly 20 percent of NICU admissions.7 In 2009, hospital charges for NAS
patients’ course of treatment averaged over $50,000.8

Prematurity and in-utero drug exposure
One study of preterm drug-exposed infants shows these infants frequently exhibit lower
Finnegan scores than term infants do on several criteria, suggesting the need for an NAS scoring
system specific for preterm infants’ symptomology.9 Despite consistent drug exposure during
gestation, preterm infants develop NAS less often than term infants. This difference could be
attributed to the NAS scoring system, which is symptom-based and is not optimized for preterm
infants; or possibly because preterm infants lack a more developed CNS.10 Premature infants,
however, are born during a critical window of gestation – a period of rapid brain development.
Dr. Allocco writes that “the combination of preterm birth and in-utero opioid exposure puts the
infant at particularly high risk for poor neurodevelopmental outcomes.” Currently, no
standardized treatment guidelines exist for preterm drug-exposed neonates. Although these
babies do not experience withdrawal in the same way, this does not necessarily indicate
decreased severity of NAS.11 The experience of in-utero drug exposure lays the foundation for
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these infants’ neurodevelopment, even if not apparent in the first few days of life. Premature
neonates are rarely studied in the context of NAS. NAS scoring requirements would exclude
nearly all of these patients from the study. The inclusion of drug-exposed premature neonates
allows us to examine what developmental impact, if any, that in-utero drug exposure has on these
infants’ development.

The role of proprioceptive input
Integration of sensory input allows the sensory systems like vestibular, proprioceptive,
and tactile systems to guide the body’s movement.12 Proprioceptors tell the body its location in
space relative to environmental features and the body itself. Kathleen Cullen writes: “The ability
to distinguish self-generated sensory events from those that arise externally is … essential for
perceptual stability and accurate motor control.”13 Proprioception plays two critical roles in
motor control. One function of proprioception is that it provides the quickest and most accurate
input with respect to detecting unexpected changes in the external environment that necessitate
alteration in movement. Secondly, proprioception provides periodic information about movement
and position during motor movements. This input influences “planning and modification of
internally generated motor commands.”14 Adequate functioning of proprioceptors is necessary
for locomotion, and proprioceptive exercises that strengthen neural connections can aid in
development of these motor control systems.
Over the past twenty or so years, Dr. Miriam Weinstein has implemented proprioceptive
cross-stroking exercises in the UTMC NICU to aid in neurodevelopment. In the plastic neonate
brain, proprioceptive input can have maximal impact. This technique can be taught to and
utilized by nurses and caregivers, so babies can receive this treatment both in and out of clinical
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settings. This paper presents a universally-available neurodevelopmental treatment for at-risk
neonates. The data used in this study comes from a larger ongoing study led by Dr. Weinstein, a
pediatric physiatrist at the University of Tennessee Medical Center (UTMC) in Knoxville,
Tennessee. The patients in this study were all seen by Dr. Weinstein in the UTMC NICU, and all
received the cross-stroking exercise intervention.
This study initially began researching the impact of these exercises on motor
development. Upon data analysis, intriguing differences in length of stay became apparent. We
discuss how the intervention has played a role in the early postnatal stage and its implications for
later in development. NAS’ potential indication for proprioceptive cross stroking exercises is
promising. We describe the role of proprioception in two of the three clusters of NAS symptoms,
Central Nervous System (CNS) and respiratory disturbances.

Methods
Dr. Weinstein, a pediatric physiatrist (PM&R), implemented cross stroking (CS) exercises
during rounds in the University of Tennessee Medical Center’s Level III NICU. Nurses
performed CS by gently holding the infant’s right hand to the left cheek, then with the back of
the right hand, stroke down the left arm all the way to the fingertips. Then the left hand repeated
this same exercise. Nurses repeated this sequence on each side three times before bringing one
hand to rest on top of the other on the chest. In addition to having sensorimotor and segmental
spinal cord components, this exercise gives afferent proprioceptive input to the motor cortex.
This free and simple hands-on technique taught to all nurses did not place undue burden on them
in the busy NICU. Besides creating an instructional video, this intervention was implemented
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with no extra equipment. Families and caregivers were also taught the intervention to encourage
involvement and maximize opportunity for the neonates to receive the exercises. Because the
NICU is very busy, the intervention’s simplicity and minimal demand of nurses’ time was of
great importance. Other therapists who rounded once a week also performed the exercises.
Following NICU discharge, PM&R monitored these patients, instructed mothers on CS and other
exercises, and coordinated care with therapists.
For this study, I reviewed all of the charts in Dr. Weinstein’s office for patients that were
exposed to drugs in-utero. These patients were divided into two categories, NAS and DrugExposed Premature. This study categorizes prematurity as infants born at 32 weeks’ gestational
age or less. Inclusion criteria eliminated some patients from the study whose charts were
originally included. UTMC uses the Finnegan scoring system to diagnose NAS. If the patients
did not have a diagnosis of “NAS” on their NICU summary, “in utero poly-substance exposure”
had to be listed as a diagnosis for inclusion; in order to analyze effects of drug-exposure in
premature patients, this was particularly important for inclusion.* For the patients who had inutero poly-substance exposure, some were not included in the study because they were not
clearly affected by the exposure; babies excluded from the study who had “in-utero polysubstance exposure” were AGA/normal-to-high birth weight, had high Apgar scores, spent
limited time in the NICU (<10 days), or only admitted to the NICU for reasons unrelated to drug
exposure. “In utero drug exposure” or “poly substance exposure” is characterized by 1)
consistent drug use self-reported by mother during pregnancy, and supported by positive urine or

*

Premature infants are rarely diagnosed with NAS, see References: 9
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Drug-Exposed Premature

Table 2. Patient demographics.

n

Mean ± SD

NAS
n

Mean ± SD

N

12

Gestational age (weeks)

12

28 3/7 ± 1.9

35

37 4/7 ± 2.4

Birth weight (grams)

12

1121.3 ± 301.9

36

2697 ± 532

1-minute Apgar score (points)

12

4.2 ± 2.2

35

7.8 ± 1.1

5-minute Apgar score (points)

12

6.6 ± 1.5

35

8.7 ± 0.9

SGA (small for gest. age)
AGA (average for gest. age)
IUGR

36

1 (8.3%)

9 (25%)

12 (91.7%)

27 (75%)

1 (8.3%)

6 (16.7%)

NICU LOS (days)

12

97.8 ± 38.6

34

20.91 ± 9.69

Walking age (months)

8

18.09 ± 4.17

23

11.7 ± 1.72

Received PT

11 (91.7%)

13 (36.1%)

Received OT

8 (66.7%)

10 (27.8%)

3 (25%)

5 (13.9%)

Received Orthodics

other samples, when available 2) neonate with positive meconium or urine sample. Another
inclusion factor required patients stay in Dr. Weinstein’s practice after discharge from the NICU,
for at least one year or until they reached developmental milestones, such as cruising and
walking (whichever occurred earliest.) Table 2 shows demographics of patients in the study.*
This study uses walking age as a measurement of development because it serves as an
important motor milestone and convenient identifier of development: Dr. Weinstein frequently
recorded walking ages in patient charts that were not initially intended for research. “Walking” is
defined as taking six or more steps independently. Because of the manner which the data was
recorded, gaps exist in available data for each patient. Of the twelve patients in the Drug-

*

table excludes outliers, explained in results
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Exposed Premature category, one left the practice before acquiring ambulation and one other had
inconclusive data in the file about their walking age. Of the thirty six NAS patients, two left the
practice before acquiring ambulation, and nine had inconclusive data about walking age
described in their charts.* In most cases walking ages were well documented, with office notes
that corroborated parent reports; some charts had a lapse of visits and in which, parent reports
were the only certain evidence of at the exact age a patient first walked independently.
Altogether, definitive walking ages have been established for 34 patients, 9 in Drug-Exposed
Premature and 25 from NAS. The length of stay in the NICU was determined for all but two
patients, one in each category. All data was obtained from patient charts. No identifying
information was recorded in data sets.
An interdisciplinary approach to medical treatments proves beneficial to patient
outcomes. Proprioceptive cross stroking constitutes just one of the interventions for NAS
treatment. Because of Knoxville’s unique geographical relation to the opioid epidemic, we also
examined some of the social history of the patients, such as type of drug exposure and postdischarge placement. This information is valuable when assessing developmental interventions in
the context of gestational drug use, maternal and prenatal care, and NAS treatment.

Results
The average gestational age of the NAS neonates was 37 weeks and 4 days (SD=2.4
days). The average birth weight for NAS was 2697 grams ± 532 grams; seventeen of the thirtysix neonates delivered were Low Birth Weight (LBW < 2500g). Drug-Exposed Premature’s
Inconclusiveness can be attributed to gaps in visits that overlapped the age at which they
began walking, or ambiguous notation in files from which a definitive walking age could not be
established
*
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average gestational age was 28 weeks and 3 days (SD=1.9 days). The average birth weight for
Drug-Exposed Premature was 1121.3 grams (SD=301.9 g). With the exception of one, all of the
Drug-Exposed Premature patients were classified Very Low Birth Weight (VLBW < 1500g).*
Twenty nine of the NAS patients were formally diagnosed with NAS.† Only one of the twelve
Drug-Exposed Premature patients was diagnosed with NAS. Six of the 36 NAS patients suffered
intrauterine growth restriction while again, only 1 of the 12 Drug-Exposed Premature patients
did. Twenty seven (75 percent) of NAS patients received pharmacologic treatment, and eight
(22.2 percent) did not receive pharmacologic treatment.‡ The difference in percentage of Small
for Gestational Age (SGA) births between non-premature and premature categories, 25 percent
vs. 8 percent, suggests a lesser effect of gestational drug-use in premature neonates.

Drug Use
Between 60 and 80 percent of newborns exposed to heroin or methadone in utero show
NAS symptoms.15 While Neonatal Abstinence Syndrome presents most frequently in the context
of gestational opiate use, other drugs are also of concern.16-18 Figure 1 shows antepartum drug
use by mothers of patients in the study. Many mothers used several drugs concurrently;
percentages are not mutually exclusive.
Of the 48 moms of babies in the study, 41 used narcotic pain relievers (including illicit
drugs, opiates/opioids, and opiate replacements.) The seven who did not use narcotic pain
relievers during pregnancy used at least one of the following drug types: benzodiazepines,
*

The one VLBW exception was LBW

†

Inclusion of non-NAS patients in NAS is explained in Length of Stay — NAS results

One chart of patient (diagnosed as NAS) was missing a NICU summary so whether they
received pharmacologic intervention is inconclusive
‡
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percentages are not
mutually exclusive

Drugs used during pregnancy
some type of opiate
antidepressants
amphetamines or stimulants
benzodiazepines or barbiturates

Figure 1.
Antepartum
drugs used
by mothers
of patients
in the study.

opi oid repl acement
opi ates or opioids
0%

10%

20%

30%

yes

40%

50%

60%

70%

80%

90% 100%

no

barbiturates, sedative-hypnotics, anxiolytics, amphetamines, or stimulants. Though tobacco does
not cause Neonatal Abstinence Syndrome, it mediates increased NAS peak scores, and impacts
the timing of the course of NAS, when used in conjunction with methadone.19 Roughly 91
percent of mothers of babies in this study used tobacco or nicotine patches regularly. Forty seven
percent used marijuana during pregnancy. Studies have shown mixed outcomes of gestational
marijuana exposure, with no certain fetal abnormalities; some long-term behavioral and
emotional outcomes have been described, but no major withdrawal symptoms have been
observed.20
From this data, we also found that opioid replacement medication use was not the
strongest predictor of whether moms used other opiates/opioids. Antidepressant use was most
highly correlated with no maternal opiate use. Of the nine women using antepartum
antidepressants, only one used opiates/opioids; this woman did not use opiate replacement
medication. Twenty seven of the women in the study used opiates or opioid medications with no
opiate replacement treatment. Fourteen of the mothers used antepartum opiate replacement
medications, half of whom used in conjunction with opiate/opioid drugs. Figures 2 and 3 show
proportions of antepartum drug use compared with use of narcotic pain relievers.
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Figure 2 (top).
Antepartum drugs vs
opiates/opioid use.

Figure 3 (bottom).
Antepartum drugs vs
opioid replacement use.

Walking Age
Distribution of the age that patients began walking independently shown in Figure 4*;
Drug-Exposed Premature (left), NAS (right.) Tables 3 and 4 show summaries of Drug-Exposed
Premature and NAS data, respectively.

*

Outliers removed
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Acquisition of ambulation age (months)

Acquisition of ambulation age (months)

Figure 4. Distribution of walking age (months). Drug-Exposed Premature shown
left. NAS shown right.

Table 3. Drug-Exposed Premature
walking age (months) [n=8]

Table 4. NAS walking age (months)
[n=23]

Mean = 18.1 ± 4.2 (SE=1.5)
95% Mean CI [14.6, 21.6]
95% SD CI [2.8, 8.5]

Mean = 11.7 ± 1.7 (SE=0.3)
95% Mean CI [11, 12.4]
95% SD CI [1.3, 2.4]

Median = 17.5 (IQR=6)

Median = 11 (IQR=2.5)

Drug-Exposed Premature
For Drug-Exposed Premature, [n=8] the mean walking age is 18.1 months ± 4.2. The
median walking age is 17.5 months, with lower and upper quartiles being 14.5 and 20.5. One
major outlier (x=54) was excluded from the Drug-Exposed Premature data. After the removal of
the 54 months outlier, another data point (x=26 months) became a minor outlier. For
consistency’s sake, and because of the extremely small sample size, this outlier was left included
in the set for analysis. When removed, however, the average walking age [n=8] becomes 16.96
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months ± 2.89. The age at which these patients acquired independent ambulation exceeds the age
for typical children but this can be attributed to compounded adverse conditions of birth and
development. No developmental studies exist to which we can compare these patients. All but
one of these patients received extra therapies (physical therapy, occupational therapy, orthotic
devices) beyond the cross-stroking exercises and at-home exercises assigned by Dr. Weinstein.

NAS
The mean walking age of NAS patients [n=23] is 11.7 months ± 1.72, 95% Mean CI
[10.95, 12.44]. The median walking age for NAS is 11 months, with the lower and upper quartile
values being 10.5 and 13 months, respectively. We determined definitive walking ages for 25
patients but for this data set, two outliers were excluded, 18.5 months and 23.5 months. Before
the data point with the value 23.5 was removed, the 18.5 month data point was only a minor
outlier; after removal of 23.5 however, 18.5 months became a major outlier as well, so it was
also removed. Receiving other therapies did not affect the age at which infants acquired
independent ambulation (Table 5). Neonates discharged to their mothers showed greater
Table 5. Walking ages

— NAS

compliance compared to those discharged to

Received other
therapy treatments*
[n=9]

Mean walking age
(months) = 11.6875
SD = 1.41, SE=0.5
95% Mean CI [10.51,
12.86]

other family members or foster families.*

Did not receive other
therapy treatments*
[n=14]

Mean walking age
(months) = 11.7
SD=1.91, SE=0.49
95% Mean CI [10.64,
12.76]

*PT, OT, orthotic
devices

*

Other patients less frequently had exact
walking ages recorded in their charts, which
indicate that they missed appointments more
frequently or had large gaps in treatment
during critical periods of development. Of the

This includes patients discharged to mothers under the supervision of other family members
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twenty-three patients included in the walking data, fourteen patients were discharged from the
NICU to their mothers, grandparents, or other family (occasionally through foster care.) Nine
NAS patients were placed in foster care with non-family members upon discharge. These nine
patients began independently walking slightly later, at 12 ± 1.3 months, than their family-placed
counterparts who walked at 11.2 ± 1.6 months.

Length of Stay (LOS)
Drug-Exposed Premature
The average LOS for our Drug-Exposed

Figure 5. Length of stay (days) for
Drug-Exposed Premature.

Premature patients is 99.3 ± 40.2 days, 95%

days with the IQR parameters being 70 and
123. Length of stay for Drug-Exposed
Premature patients was not correlated with

Length of stay (days)

Mean CI [72.3, 126.3]. The median LOS is 100

birth weight. Drug-exposed premature Apgar
scores for 1- and 5-minutes averaged 4 ± 2, and
6.5 ± 1.5, respectively. Figure 5 shows the LOS
distribution and Table 6 shows corresponding
summary statistics.

Table 6. Length of Stay (Days) for DrugExposed Premature [n=11]
Mean = 99.3 ± 40.2 (SE=12.1)
95% Mean CI [72.3, 126.3]
95% SD CI [28.1, 70.5]
Median = 100 (IQR=53)
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Length of stay (days)

Figure 7. LOS of NAS patients
diagnosed as NAS in the NICU.

Length of stay (days)

Figure 6. Length of stay (days) of all
NAS patients.

Table 7. Length of Stay (Days) of all
NAS patients [n=34]

Table 8. Length of Stay (Days) of all
NAS patients diagnosed NAS [n=27]

Mean = 20.9 ± 9.7 (SE=1.7)
95% Mean CI [17.5, 24.3]
95% SD CI [7.8, 12.8]

Mean = 21 ± 9.4 (SE=1.8)
95% Mean CI [17.3, 24.7]
95% SD CI [7.4, 12.8]

Median = 21 (IQR=16)

Median = 21 (IQR=16)

NAS
Data was only available for 34 of the 36 NAS patients due to NICU summaries missing in
two of the charts. Distribution shown in Figure 6, and summary statistics in Table 7. Neonates
stayed in the NICU, on average, for 20.9 days ± 9.4. The median LOS was 21 days, with the
upper and lower interquartile values being 12 and 28 days, respectively. Birth weight did not
significantly influence LOS; LBW neonates and non-LBW neonates average length of stays were
20.6 and 21.2, respectively. Twenty-nine of the patients in this category were diagnosed as
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“NAS.” Only one patient who was diagnosed as NAS did not receive pharmacologic treatment;
this patient stayed in the NICU for only 5 days - the shortest length of stay of all patients in the
study.* Seven of the thirty six patients in the NAS category were not diagnosed NAS in the
NICU, but were diagnosed with “in-utero poly substance exposure” and included in the study.
Figure 7 shows distribution of the patients in the study who did receive NAS diagnosis; summary
statistics shown in Table 8. These patients’ average length of stay was 21 days ± 9.7. The length
of stay for patients who did receive NAS diagnosis was not significantly different than from the
whole of patients in the category. For patients that did not receive NAS diagnosis, the average
LOS was 20.6 days ± 11.7. There was only one patient who did receive NAS diagnosis that did
not receive pharmacological treatment. Creating a sample of all patients who were diagnosed as
NAS and received pharmacologic treatment involves removal of only a single data point, and
thus, had negligible impact on the LOS.

Discussion
The Drug-Exposed Premature category is a very small sample size of all drug-exposed
premature neonates. These statistics should be interpreted as insights into the condition of drug
exposed neonates, rather than statistics that are descriptive of all drug-exposed neonates. The
differences between drug-exposed premature patients and non-drug-exposed premature patients
highlights the need for continued research of this patient population.

The two patients whose NICU summaries I could not find (thus, LOS = unknown) were both
diagnosed NAS
*
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Drug use
Because the sample size is extremely small, further studies should assess the validity of
the claim that antidepressant use is correlated with less opiate use. * Another possible explanation
for this correlation is that a therapeutic regimen for depression may indicate better access to
medical professionals, and these women are more likely to be using replacement therapy than
illicitly using drugs. Additional evidence supporting this possibility is that women who took
antidepressants while pregnant were much more likely to use benzodiazepines - indicating they
potentially received psychiatric treatment. Lapses in documentation of the medication/drug
sources pose limitations to this study; it is possible that women using opiate replacement
medications obtained them illicitly, used them unmonitored by providers, or abused them by
using them at unprescribed frequencies or dosages. Meanwhile, some women claimed they used
prescription pain relievers, but prescriptions were not always confirmed.

Walking Age
Drug-Exposed Premature
All but one of the patients in our study received other therapies, including physical
therapy, occupational therapy, and orthotic devices. Even after receiving these therapies and the
cross-stroking exercises, these patients began walking independently at around 18 months. When
for controlling for gestational age, studies have shown that premature infants attain independent
ambulation at a later age than term infants. Our patients independently walked later than other
premature infants. Drug-Exposed Premature patients walked much later (M=18.1 months,
SD=4.2) than the non-premature NAS patients (M=11.7, SD=1.72.) The Apgar scores for our
*

n(women who used antidepressants) = 9
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patients (1-Minute M=4.2, 5-Minute M=6.6) averaged about two points lower than Apgar scores
for other premature patients.21 These lower Apgar scores support the theory that effects of
prematurity and drug-exposure likely compound to result in greater adverse outcomes.

NAS
The NAS group’s walking age (M=11.7 months, SD=1.72.) is typical for children, with
documented average age being around 12 months.22 Limited research exists on NAS’ long-term
developmental impact, but data from this study shows these babies reach the “walking
independently” motor milestone slightly before the average. These “slightly before the average”
ages can most likely be attributed to a smaller sample size, as well as the fact that these children
received the cross-stroking therapy both in the NICU and at home, as well as at-home exercise
plans Dr. Weinstein gave. The thirteen patients* discharged from the NICU to family members
(including mothers) walked earlier (M=11.2 months, SD=1.6) than the nine patients placed with
non-family foster care (M=12 months, SD=1.3). This difference is small, but likely attributed to
family members being more familiar with the condition of the patient and exercise plans than
foster parents. Patients discharged to non-familial foster care had more gaps in treatment than
those discharged to family. Foster parents were instructed on the exercises before discharge but
family who spent more time in the NICU with the patients likely performed the exercises more
frequently and were more familiar with them post-discharge.

NICU discharged fourteen patients with family, but one outlier (15.5 months) was excluded
from this data set
*
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Length of Stay
Drug-Exposed Premature
The length of stay in the Drug-Exposed Premature category did not shorten; in fact, the
length of stay for these patients was longer than the average premature neonates’ stay. One study
of thousands of newborns’ NICU stays found the neonates born at 28 weeks’ gestation resided in
the NICU for 66 days on average; for 30 weeks the stay averaged 48 days.23 There is very little
data on NAS and prematurity but our data suggests that drug exposure necessitates a much
longer stay than for non-exposed premature neonates. Because the Finnegan scoring system is
symptom-based, many drug-exposed premature neonates may not qualify for an NAS diagnosis,
and thus elude NAS care. This lapse in treatment could explain longer NICU stays for these
patients. Though limited (N=12), this data indicates a need for greater research on the impact of
in-utero drug exposure in the context of prematurity.

NAS
The similar lengths of stay between NAS and non-NAS neonates justifies the inclusion of
these neonates who were drug-exposed but not formally diagnosed as NAS in the study. NonNAS neonates in the NAS category stayed in the NICU an inappreciably less length of time; one
that is not statistically significant. This suggests a discrepancy in diagnoses rather than actual
conditions of the infant, likely caused by providers coding diagnoses differently and non-uniform
Finnegan scoring usage. This inclusion does not, however, extend to all drug-exposed neonates.
Including these patients shows disparities in diagnosis and treatment of NAS. Rather than assert
drug exposure warrants NAS diagnosis, this data demonstrates the possibility that not all
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neonates are evaluated in the same fashion. Of course there are always exceptional cases; the one
patient who was diagnosed NAS and did not receive pharmacologic treatment was sent home
after just 5 days.
Proprioceptive cross-stroking points to decreased length of stay for babies with NAS
cases that warranted NICU stay. Though we have not explored what symptomology has been
specifically impacted by proprioceptio, we have identified proprioception’s role in two of the
three main foci of NAS pathology, the CNS and respiratory disturbances. Both hospitals and
families have a vested interested in reducing length of stay; longer length of stay places both
under financial strain, and also results in psychosocial strain on families and patients. One 2003
study found the average length of stay for NAS neonates to be 30 days.24 Another study
comparing pharmacologic treatments found the average length of stay of neonates treated with
the most effective pharmacologic combination in the study to be 38 days.25 Before a years-long
NICU LOS reduction effort by a multidisciplinary task-force in Ohio, the NICU LOS in the
hospital system for NAS neonates averaged 36 days.26 A study comparing LOS associated with
treatment by methadone and an oral morphine preparation found the average length of stays to be
40 and 36 days, respectively.27

Why the shorter length of stay?
The shorter LOS seen in NAS patients who received cross-stroking exercises could be
attributed to the plasticity in the young neonate brain; providers and caregivers can utilize this
plasticity to regulate CNS functioning in vulnerable neonates. Neonates, just as adults,
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experience increased pain sensitivity and an exaggerated pain response during opiate withdrawal.
The CNS processes afferent input received from proprioceptors.28
Interventions can reduce pain directly “by blocking nociceptive transduction or
transmission or by activation of descending inhibitory pathways…” Opioids are the staple for
pharmacotherapy for direct pain management in neonates, but these drugs can have adverse
developmental effects.29,30 Indirect non-pharmacological means of reducing pain in neonates
include environmental measures, breastfeeding, and skin-to-skin contact.31
One animal study of acute opiate withdrawal shows evidence of neonatal rats
experiencing allodynia * and hyperalgesia in this context.32 In neonates, this confusion in afferent
input is in part due to the plasticity of the brain. Peripheral proprioceptive neurons converge onto
central nociceptive neurons in the dorsal horn, where they have the opportunity to activate
nociceptors. In adults with normal afferent activity, and with no nerve or tissue damage, the
synaptic locales of the neurons is inconsequential. Neural plasticity, however, can sensitize
nociceptors to the proprioceptors’ activity, which causes the neonate to perceive normal
proprioceptive input as painful. Just as pain can be “learned” through neural plasticity, it can be
unlearned through regular afferent input.33,34 The early postnatal stage is critical for neural
plasticity, specifically, dorsal horn plasticity.35 Proprioceptive cross-stroking provides consistent
peripheral afferent input that can mediate the fine-tuning of these connections in the dorsal horn.
36,37

In the short-term, could aid the neonate in self-regulatory soothing. In the long-term, this

could help correct the maturation process of afferent input innervation. Proprioceptive input

Allodynia is a conditioned in which a normal, non-painful stimulus, such as clothes touching
the skin, causes an abnormal or painful sensation)
*
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reduces length of stay by promoting CNS development and fine-tuning the CNS response to
allodynia secondary to drug-withdrawal.38
Repetitive pain exposure can cause permanent changes to the immature pain system of
the neonate.39 Early repetitive pain exposure contributes to altered pain thresholds and
physiological responses, as well as adverse neurodevelopmental outcomes.40-42 All potential
ways to reduce the risk of these unfavorable outcomes should be evaluated.
Drug-exposed neonates often have signs of respiratory disturbances including increased
respiratory rate, transient tachypnea, chest retractions, and nasal flaring. NAS patients frequently
require cardiopulmonary assistance such as supplemental oxygen, ventilation, and intubation.43
One study has shown that proprioceptive limb stimulation in premature neonates has reduced the
number of breathing pauses and intermittent hypoxia. Proprioceptive interventions can increase
breathing and synchronize breathing patterns with limb movement. Neuromodulation of
proprioceptive afferents offers a non-invasive and low-cost method to reduce aberrant breathing
episodes; these interventions promote neural and pulmonary development, rather than reliance on
mechanical and pharmacologic agents, which pose risks to the development of these structures.44

Limitations and further research
Many length of stay studies disproportionately exclude many of the patients that
inevitably have longer NICU stays. Some studies show NAS neonates with a shorter average
NICU stay than our patients. A quarter of the NICU sites in paper that published results from a
years-long task force were Level II NICUs; this study also excluded patients born <35 weeks’
gestation.45 UTMC’s Level III NICU is equipped to handle more severe NAS cases; neonatal
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teams at other hospitals in the area care for drug-dependent neonates who do not have severe
enough symptoms to warrant NICU admission.49 Another study with a shorter LOS than our
paper excluded “not otherwise well newborns” and those born less than 35 weeks’ gestation. It
also included NAS patients who were placed in the pediatric unit; thus, it included many patients
who exhibited less severe NAS cases.46 The newborns in our study all resided in the NICU
before the hospital created major initiatives to optimize the NICU environment for these babies.
Other studies with similar shorter lengths of stay have excluded with mothers who engage in
poly-drug uses.47,48 Nearly all of the mothers in our study used multiple drugs during pregnancy
so these factors could not be isolated in our patients. Across both categories, only 23 percent
(seven) of our patients exposed to narcotic pain relievers were exposed to only opiate
replacement medications; and of these seven patients, six were exposed to at least one of the
other drugs listed in Table 1. Additionally, over 90 percent of the mothers in our study
consistently used tobacco, which is known to prolong and increase NAS symptoms.50 Patients
born at less than 35 weeks’ gestation comprised roughly 20 percent of our NAS patients. Unlike
large and expensive multidisciplinary initiatives to reduce length of stay, our NICU implemented
simple and free exercises in addition to the pharmacologic treatment which resulted in an
average LOS of 21 days.
Some papers have shown increases in length of stay as the opioid epidemic unfolds in the
United States.51 Being in the foothills of Appalachia, the opioid epidemic’s presence here
outdates, and prevalence here exceeds other regions. In addition to types of drugs used, we
believe geography may have a role in the length of stay in our patients as well.52
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Based on this preliminary study, future research will focus on length of stay for NAS

patients. In order to maximize the studies to which we can compare our data, we hope to control
for factors, such as co-occurring drug use, prematurity, and severity as previously mentioned
papers have done. We recognize the impact post-discharge placement has on length of stay as
well, and plan to control for babies who were not discharged as soon as they were ready to
leave.* The study’s small sample size limits the extent to which we can examine differences
between groups including post-discharge placement circumstances, type of drug exposure,
pharmacologic treatment received and length of pharmacologic treatment, and more. Additional
literature regarding nicotine from cigarettes and methadone maintenance therapy (and perhaps,
all opiates) should be reviewed for the next study because our patients reported tobacco use at
much higher rates than other studies. This was shown to increase peak NAS scores and alter the
time course of NAS, which was not considered during data analysis. Because this preliminary
study excluded all patients who did not stay in Dr. Weinstein’s practice for at least one year or
until the patient began walking (whichever occurred earliest), a future study of all NAS patients’
NICU length of stays will include many more patients. The concept of proprioception’s possible
role in mediating respiration was previously only considered after data collection. We plan to
examine the impact of proprioception on respiratory function and assistance in the NICU more
closely than this study. Reduction in length of stay decreases the social and psychological strain
on families and their babies; as well as the financial strain on hospitals and patients. Reduced
length of stay could also indicate decreased pain exposure; pain exposure is associated with

One study mentions that some patients spent 1-2 extra days in the NICU while DCS or foster
care coordinated placement - something we did not consider
*
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worse developmental outcomes. While still preliminary research, this paper shows promising
future research directions in neonatology and PM&R.
Main ideas
• Proprioceptive cross stroking is a free developmental intervention that can be employed by anyone.
• Unlike mechanical and pharmacologic treatments that can have adverse neurodevelopmental
outcomes and pulmonary development, CS exercises promote self-regulatory soothing and long-term
development which can reduce hospital length of stay.
• Future research: possible role of antidepressants in reduced opiate/opioid use
• Proprioceptive input can fine-tunes plastic neural connections in the early postnatal stage to reduce
pain.
• Proprioceptive input may contribute to increased pulmonary function.
• Drug-exposed premature neonates’ NICU stay far exceeds the average premature neonates’ stay,
which displays the need for further research in this patient population and improved NAS diagnostic
tools for premature drug-exposed neonates.
• Type of drug exposure can have very diﬀerent impacts on NAS pathology, course, and timing. This
should be considered when assessing NICU stay, NICU events and associated treatments, and
proprioceptive input’s specific role in these patients’ development.
• Drug-Exposed Premature infants begin walking at a later age than their normal premature
counterparts, indicating a possible compounding eﬀect of adverse developmental conditions.
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